Authors
Latest:
Richard Rudick, MD: The CogEval App in Clinical PracticeThe goal of the free application is to make cognitive assessments routine in multiple sclerosis treatment.
Latest:
Isabelle Lambert, MD: Spike, Spindle Frequency in Hippocampus During NREM Affect Long-Term MemoryImpairment of physiological spindle activity in the hippocampus during NREM sleep by interictal epileptic activities may have negative consequences on long-term memory consolidation.
Latest:
Annette Langer-Gould, MD, PhD: Lowering Postpartum MS Relapse Rates With BreastfeedingThe regional lead in clinical and translational neuroscience at Kaiser Permanente discussed subgroup findings from a study of pregnancy in women with MS which suggested that breastfeeding in the postpartum period can drastically decrease the risk of disease relapse.
Latest:
Partnering Clinicians With Parents as a Motivator for Pediatric Epilepsy Research: Zachary Grinspan, MD, MSThe pediatric epilepsy specialist at Weill Cornell Medicine in New York City spoke on how meetings such as the 2022 AES Conference bring clinicians together as well as how parents motivate them to advance pediatric epilepsy research. [WATCH TIME: 6 minutes]
Latest:
Study Findings Provide New Hope for Patients With Multiple SclerosisMultiple sclerosis affects nearly 3 million patients worldwide; new research is helping pave the way for developing new therapies and medications that get at the defining mechanisms that trigger immune regulation loss of this unpredictable central nervous system disease.
Latest:
Jeffrey L. Cummings, MD, ScD: Optimal Therapeutic Targets for Addressing Alzheimer DiseaseThe director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair of the department of brain health at the University of Nevada Las Vegas spoke about therapies under investigation for the treatment of Alzheimer disease.
Latest:
Eva Winnebeck, PhD: Temporal Dynamics of SleepThe postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.
Latest:
Aducanumab's Unlikely Road to the FDA: Is Approval Imminent?Recent news that the FDA has granted the fastest possible review for Biogen’s Alzheimer disease treatment aducanumab may be indicative of the agency’s increasing confidence in the drug.
Latest:
Ways to Align Patient Characteristics of Progressive Multiple Sclerosis Trials With Clinical Reality: Robert J. Fox, MDThe staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed how the CALLIPER trial’s lower proportion of patients with gadolinium-enhancing lesions mirrors clinical practice more closely than other progressive MS trials. [WATCH TIME: 2 minutes]
Latest:
The Changing Landscape of Preventative Migraine TreatmentsA panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.
Latest:
Future Improvements in the Management of NarcolepsyExpert neurologists discuss advancements in the management of narcolepsy including new drug formulations and provide take-home messages for how to improve diagnosis and treatment in the future.
Latest:
Using Prior Success to Improve Alzheimer Trials, Drug Development: Jeffrey Cummings, MD, ScDThe director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada, Las Vegas discussed how the momentum gained within the Alzheimer community can springboard success going forward. [WATCH TIME: 4 minutes]
Latest:
Gill Livingston, MBChB, MD: Challenges of Sleep Difficulties in People Living with DementiaLivingston spoke to a number of topics in the dementia space, including the challenges clinicians face and her hope for the future.
Latest:
Raymond S. Turner, MD, PhD: Safety Results for Nilotinib in AlzheimerThe director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.
Latest:
What You Need to Know About Amantadine for Parkinson DiseaseThis guide includes everything you need to know about amantadine (Osmolex ER, Osmotica Pharmaceuticals) for the treatment of Parkinson disease and drug-induced extrapyramidal reactions in adults.
Latest:
Pouya Ghaemmaghami, PhD: Predicted Gene Expression and the Association with Sleep MacrostructurePreliminary results show that the whole genome information can be used to assess the association between predicted gene expression in different parts of the brain and sleep, suggesting where brain genes are expressed matter for variability in sleep.
Latest:
Eyiyemisi Damisah, MD: Additional Insights Into Cell DeathThe assistant professor of neurosurgery at Yale School of Medicine discussed what doors have been opened by a recent study of the cell death process she and colleagues conducted.
Latest:
Shared Decision-Making in Multiple Sclerosis TreatmentAhmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the need for shared decision-making in MS care.
Latest:
Treatment Gaps Among Elders With Generalized Epilepsy: Vineet Punia, MD, MSThe neurologist at Cleveland Clinic addressed aspects of care for elders with generalized epilepsy that need to be further researched.
Latest:
Expanding the Use of Seizure Apps for Epilepsy: Jessica Fesler, MD, MEdThe staff epileptologist at Cleveland Clinic’s Epilepsy Center discussed new untapped ways seizure apps could help patients with epilepsy. [WATCH TIME: 2 minutes]
Latest:
David Llewellyn, PhD: The Impact of Lifestyle Factors on Genetic Risk in DementiaThe associate professor of neuroepidemiology and digital health spoke about the importance of findings from an observational study which showed that adherence to a healthy lifestyle can offset the genetic risk for dementia.
Latest:
David Leppert, MD: Building a Foundation for Neurofilament LightThe therapeutic head of neuroinflammation and pain at Novartis spoke about his desire to work to a point where physicians can use NfL to monitor disease activity, make therapeutic decisions, and give perspective to patients.
Latest:
Introducing DaxibotulinumtoxinA-Ianm as a Treatment Option for Cervical Dystonia: Peter J. McAllister, MD, FAANThe chief medical officer of New England Center for Neurology and Headache talked about trends observed in the clinical practice with Daxxify, a long-acting botulinum toxin for patients with cervical dystonia. [WATCH TIME: 5 minutes]
Latest:
Sigma-1 Agonists Offer Combination Approach to Dementia SymptomsResearch from the past decade suggests that sigma-1 receptors and their encoding gene, SIGMAR1, together act as a therapeutic target for patients with dementia.
Latest:
Ian Miller, MD: Adapting AAV Gene Therapy for SCN1A-Positive EpilepsyThe medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital discusses his early stage gene therapy trial for Dravet syndrome.
Latest:
Early High-Efficacy TreatmentJames Stankiewicz, MD, provides an overview of the burden of multiple sclerosis and discusses early, high-efficacy treatment of the disease.
Latest:
Peter Calabresi, MD: Utilizing A Uniform Biomarker AssayFor the director of the Johns Hopkins Multiple Sclerosis Center, a biomarker is perhaps only as useful as the clinician community’s ability to read out its measurements.
